Journal of clinical & experimental oncology最新文献_第7页

Prognostic Implications of Hyaluronic Acid Binding Protein 1 (HABP1) Expression, Estrogen Receptor (ER) and Progesterone Receptor (PR) Loss in Endometrial Carcinoma 子宫内膜癌中透明质酸结合蛋白1 (HABP1)表达、雌激素受体(ER)和孕激素受体(PR)缺失对预后的影响

Journal of clinical & experimental oncology

Pub Date : 2017-10-04 DOI: 10.4172/2324-9110.1000199

O. Harb, M. Elfeky, O. Elfarargy, Rham Z. Ahmed, S. Balata, A. Alnemr

Background: Endometrial carcinoma (EC) is the 4th commonest female cancer and the commonest gynecological tract malignancy. The prevalence rate is increasing; mainly in developing countries and the prognosis for recurrent or advanced EC are poor. The 5-year survival rates of EC patients are poor especially in women with metastatic EC. These bad outcomes need novel prognostic and predictive markers for EC for better managements of patients. Hyaluronic acid binding protein 1 (HABP1), which has a specific affinity toward hyaluronan (HA), was primarily discovered in cervical carcinoma (HeLa) cells. It is a eukaryotic protein conserved and ubiquitously found in multiple organisms; yeasts and humans. HABP1 expression, clinicopathological and prognostic importance in endometrial carcinoma is still not sufficiently clarified. Estrogen Receptor (ER) and Progesterone Receptor (PR) are biological molecules that have been studied as prognostic markers because of their essential physiological rules. Molecular biology advancements allow introduction of these hormone receptors to expect outcome of many cancers, e.g. ovarian, breast and EC. Aim: The aim of that study was to explore the expressions of HABP1, ER and PR in endometrial carcinoma patients, correlating their expressions with clinic-pathological factors and prognosis of patients. Methods: HABP1, ER and PR expressions were evaluated in sections from 60 paraffin blocks of EC. We analyzed correlations between the levels of markers expressions and prognosis of our patients. Results: HABP1 was expressed in 61% of EC. ER and PR were high in 56% and 63% of the patients, respectively. HABP1 expression, ER and PR loss were significantly associated with disease progression, disease free survival and poor overall survival (p=0.001, p=0.001and p=0.001, respectively). Conclusion: HABP1 high expression with ER and PR loss are markers of poor pognosis of EC patients.

背景:子宫内膜癌是最常见的女性肿瘤，也是最常见的妇科恶性肿瘤。患病率正在上升;主要发生在发展中国家，复发性或晚期EC的预后很差。EC患者的5年生存率很低，尤其是女性转移性EC患者。这些不良结果需要新的预后和预测标记物来更好地管理EC患者。透明质酸结合蛋白1 (HABP1)主要在宫颈癌(HeLa)细胞中发现，它对透明质酸(HA)具有特异性亲和力。它是一种保守的真核蛋白，普遍存在于多种生物中;酵母和人类。HABP1在子宫内膜癌中的表达、临床病理和预后重要性尚不清楚。雌激素受体(Estrogen Receptor, ER)和孕激素受体(Progesterone Receptor, PR)是两种具有重要生理规律的生物分子，作为预后标志物被广泛研究。分子生物学的进步允许引入这些激素受体来预测许多癌症的结果，例如卵巢癌、乳腺癌和EC。目的:探讨HABP1、ER和PR在子宫内膜癌患者中的表达情况及其与临床病理因素和患者预后的关系。方法:测定60块EC石蜡切片HABP1、ER和PR的表达。我们分析了标志物表达水平与患者预后之间的相关性。结果:HABP1在61%的EC中表达。ER和PR分别在56%和63%的患者中较高。HABP1表达、ER和PR缺失与疾病进展、无病生存期和总生存期差显著相关(p=0.001、p=0.001和p=0.001)。结论:HABP1高表达伴ER和PR缺失是EC患者预后不良的标志。

{"title":"Prognostic Implications of Hyaluronic Acid Binding Protein 1 (HABP1) Expression, Estrogen Receptor (ER) and Progesterone Receptor (PR) Loss in Endometrial Carcinoma","authors":"O. Harb, M. Elfeky, O. Elfarargy, Rham Z. Ahmed, S. Balata, A. Alnemr","doi":"10.4172/2324-9110.1000199","DOIUrl":"https://doi.org/10.4172/2324-9110.1000199","url":null,"abstract":"Background: Endometrial carcinoma (EC) is the 4th commonest female cancer and the commonest gynecological tract malignancy. The prevalence rate is increasing; mainly in developing countries and the prognosis for recurrent or advanced EC are poor. The 5-year survival rates of EC patients are poor especially in women with metastatic EC. These bad outcomes need novel prognostic and predictive markers for EC for better managements of patients. Hyaluronic acid binding protein 1 (HABP1), which has a specific affinity toward hyaluronan (HA), was primarily discovered in cervical carcinoma (HeLa) cells. It is a eukaryotic protein conserved and ubiquitously found in multiple organisms; yeasts and humans. HABP1 expression, clinicopathological and prognostic importance in endometrial carcinoma is still not sufficiently clarified. Estrogen Receptor (ER) and Progesterone Receptor (PR) are biological molecules that have been studied as prognostic markers because of their essential physiological rules. Molecular biology advancements allow introduction of these hormone receptors to expect outcome of many cancers, e.g. ovarian, breast and EC. \u0000Aim: The aim of that study was to explore the expressions of HABP1, ER and PR in endometrial carcinoma patients, correlating their expressions with clinic-pathological factors and prognosis of patients. \u0000Methods: HABP1, ER and PR expressions were evaluated in sections from 60 paraffin blocks of EC. We analyzed correlations between the levels of markers expressions and prognosis of our patients. \u0000Results: HABP1 was expressed in 61% of EC. ER and PR were high in 56% and 63% of the patients, respectively. HABP1 expression, ER and PR loss were significantly associated with disease progression, disease free survival and poor overall survival (p=0.001, p=0.001and p=0.001, respectively). \u0000Conclusion: HABP1 high expression with ER and PR loss are markers of poor pognosis of EC patients.","PeriodicalId":73658,"journal":{"name":"Journal of clinical & experimental oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42807875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Tongue Reconstruction with Submental Flap: An Observational Study 颏下皮瓣舌重建:一项观察性研究

Journal of clinical & experimental oncology

Pub Date : 2017-10-04 DOI: 10.4172/2324-9110.1000195

A. Kushwaha

Objective: Successful tongue reconstruction should restore swallowing, speech function, and cosmesis. This study was done to evaluate the functional outcomes of tongue reconstruction using submental flap for tongue defects. Method: From August 2016 to June 2017, patients receiving submental flap for tongue reconstruction were included in the study. All patients had class II defect after surgery. Speech intelligibility score and swallowing assessment were done for functional evaluation. Results: Total seven patients underwent submental flap reconstruction for tongue defect during the study period. Speech intelligibility assessment showed good outcome in 5 and acceptable outcome in 2 patients. Swallowing assessment showed good MTF score in 6 and acceptable score in 1 patient. There was no local recurrence. Conclusion: Submental flap is good alternative for tongue reconstruction in patient with class II defects after surgical resection.

目的：成功的舌头重建应能恢复吞咽、言语功能和美容。本研究旨在评估颏下舌瓣修复舌缺损的功能效果。方法：2016年8月至2017年6月，接受颏下舌瓣重建的患者纳入研究。所有患者术后均为Ⅱ级缺损。进行语音清晰度评分和吞咽评估以进行功能评估。结果：在研究期间，共有7名患者因舌缺损接受了颏下皮瓣重建。5例患者的语音清晰度评估结果良好，2例患者的结果可接受。吞咽评估显示6名患者MTF评分良好，1名患者评分可接受。没有局部复发。结论：颏下皮瓣是II类缺损患者术后舌再造的良好选择。

引用次数: 0

Post Mastectomy Pain Syndrome- Role of Preservation of Intercostobrachial Nerve: A Retrospective Analysis in Breast Cancer Patients in Jharkhand 乳房切除术后疼痛综合征-保留臂间神经的作用：贾坎德邦癌症乳腺癌患者的回顾性分析

Journal of clinical & experimental oncology

Pub Date : 2017-09-25 DOI: 10.4172/2324-9110.1000196

A. Kushwaha, T. Kumar

Background: Post mastectomy pain syndrome is experienced by 20 to 30 % patient after breast surgery. Sectioning of the intercostobrachial nerve during breast surgeries is thought to be dominant cause this chronic neuropathic pain. We evaluate the role of preservation of intercostobrachial nerve in post mastectomy pain syndrome. Method: Twenty patients were retrospectively divided into two groups. 08 patients in group A underwent preservation of intercostobrachial nerve and in Group B which included 12 patients nerve was sectioned. Pain assessment was done subjectively on 3 months and 6 months post-operatively by visual analogue scale. Results: The average time taken for surgery in group a patient was 90 minutes and in group B was 82 minutes. The BMI was also slightly higher in group B patients. Difference in pain score was not stastically significant at the end of three months (p=0.052); however the difference in pain score was stastically significant at the end of 6 months (p=0.027) between the groups. Conclusion: Preservation of intercostobrachial nerve prevents post mastectomy pain syndrome; however larger randomized studies are required for further verification of results.

背景：20%至30%的患者在乳腺手术后会出现乳房切除术后疼痛综合征。乳腺手术中肋间臂神经的切断被认为是这种慢性神经性疼痛的主要原因。我们评估保留肋间臂神经在乳房切除术后疼痛综合征中的作用。方法：将20例患者随机分为两组。A组08例保留肋间臂神经，B组12例切除肋间臂。术后3个月和6个月采用视觉模拟量表进行主观疼痛评估。结果：a组患者平均手术时间为90分钟，B组为82分钟。B组患者的BMI也略高。疼痛评分的差异在三个月结束时没有统计学意义（p=0.052）；然而，在6个月结束时，两组之间的疼痛评分差异具有统计学意义（p=0.027）。结论：保留肋间臂神经可预防乳房切除术后疼痛综合征；然而，需要更大规模的随机研究来进一步验证结果。

{"title":"Post Mastectomy Pain Syndrome- Role of Preservation of Intercostobrachial Nerve: A Retrospective Analysis in Breast Cancer Patients in Jharkhand","authors":"A. Kushwaha, T. Kumar","doi":"10.4172/2324-9110.1000196","DOIUrl":"https://doi.org/10.4172/2324-9110.1000196","url":null,"abstract":"Background: Post mastectomy pain syndrome is experienced by 20 to 30 % patient after breast surgery. Sectioning of the intercostobrachial nerve during breast surgeries is thought to be dominant cause this chronic neuropathic pain. We evaluate the role of preservation of intercostobrachial nerve in post mastectomy pain syndrome. \u0000Method: Twenty patients were retrospectively divided into two groups. 08 patients in group A underwent preservation of intercostobrachial nerve and in Group B which included 12 patients nerve was sectioned. Pain assessment was done subjectively on 3 months and 6 months post-operatively by visual analogue scale. \u0000Results: The average time taken for surgery in group a patient was 90 minutes and in group B was 82 minutes. The BMI was also slightly higher in group B patients. Difference in pain score was not stastically significant at the end of three months (p=0.052); however the difference in pain score was stastically significant at the end of 6 months (p=0.027) between the groups. \u0000Conclusion: Preservation of intercostobrachial nerve prevents post mastectomy pain syndrome; however larger randomized studies are required for further verification of results.","PeriodicalId":73658,"journal":{"name":"Journal of clinical & experimental oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45792481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Expressions of Orphan Nuclear Receptor TR3/Nur77 in Chronic Hepatopathy and Its Clinical Significance. 孤儿核受体TR3/Nur77在慢性肝病中的表达及临床意义

Journal of clinical & experimental oncology

Pub Date : 2017-08-01 DOI: 10.4172/2324-9110.1000188

Yingling Zeng, Xiaoguang Ye, Degui Liao, Shizhang Huang, Huinan Mao, Dezheng Zhao, Huiyan Zeng

Objective: Although great success has been achieved in cancer treatment, current cancer therapies, including anti-tumorigenesis and anti-angiogenesis, still face the problems of insufficient efficacy, resistance and intrinsic refractoriness, in addition to their toxic side effects. There is a demand to identify additional targets that can be blocked to turn off the downstream effects of most, if not all, pathways. Our studies suggest that orphan nuclear receptor TR3 (human)/Nur77 (mouse) is such a target. Most recently, we reported that TR3/Nur77 expression in human hepatic cancer tissues correlates well with tumor progress, suggesting that TR3 is a specific therapeutic target for hepatic cancers. However, the correlation of TR3/Nur77 expression in hepatocellular carcinoma (HCC) with chronic hepatitis has not been studied.

Methods: The expression of TR3/Nur77 was analyzed in human primary hepatic cancer specimens from patients that have complete medical records with Immunohistochemically staining. The statistical analysis was used to access the significance of TR3 expression in tumor tissues, cirrhosis tissues and chronic hepatitis tissues with and without hepatitis B virus infection (HBV(+) and HBV(-)), which were obtained from para-tumor tissues.

Results: The positive rates of TR3/Nur77 expression in hepatocellular carcinoma, cancerous liver cirrhosis and chronic hepatitis are 66.67%, 30%, and 20%, respectively, which are statistic significant (p<0.05). The positive rates of TR3/Nur77 expression in hepatocellular carcinoma are statistic significant (p<0.05) with 81.25% and 20% in HBV (+) or HBV (-), respectively.

Conclusion: The positive expression rate of TR3/Nur77 in hepatocellular carcinoma is higher than that in chronic hepatitis and cirrhosis. The positive rate of TR3/Nur77 expression in hepatocellular carcinoma is higher with HBV infection than that without infection. Our results suggest that TR3/Nur77 plays an important role in the progression of chronic hepatitis, and the occurrence and development of HCC.

目的:虽然癌症治疗取得了巨大的成功，但目前的癌症治疗方法，包括抗肿瘤和抗血管生成，仍然面临着疗效不足、耐药和内在难治性的问题，以及毒副作用。有必要确定可以阻断的其他靶标，以关闭大多数(如果不是全部的话)途径的下游影响。我们的研究表明孤儿核受体TR3(人)/Nur77(小鼠)就是这样一个靶点。最近，我们报道了TR3/Nur77在人肝癌组织中的表达与肿瘤进展密切相关，这表明TR3是肝癌的特异性治疗靶点。然而，TR3/Nur77在肝细胞癌(HCC)中表达与慢性肝炎的相关性尚未研究。方法:采用免疫组化染色法对病历完整的人原发性肝癌标本中TR3/Nur77的表达进行分析。采用统计学方法分析TR3在肿瘤组织、肝硬化组织和慢性肝炎组织(伴和不伴乙型肝炎病毒感染的HBV(+)和HBV(-))中表达的意义。结果:TR3/Nur77在肝细胞癌、癌性肝硬化和慢性肝炎中的表达阳性率分别为66.67%、30%和20%，差异均有统计学意义(p)结论:TR3/Nur77在肝细胞癌中的表达阳性率高于慢性肝炎和肝硬化。肝细胞癌中TR3/Nur77表达阳性率在HBV感染组高于未感染组。我们的研究结果提示，TR3/Nur77在慢性肝炎的进展和HCC的发生发展中起着重要作用。

{"title":"Expressions of Orphan Nuclear Receptor TR3/Nur77 in Chronic Hepatopathy and Its Clinical Significance.","authors":"Yingling Zeng, Xiaoguang Ye, Degui Liao, Shizhang Huang, Huinan Mao, Dezheng Zhao, Huiyan Zeng","doi":"10.4172/2324-9110.1000188","DOIUrl":"https://doi.org/10.4172/2324-9110.1000188","url":null,"abstract":"Objective: Although great success has been achieved in cancer treatment, current cancer therapies, including anti-tumorigenesis and anti-angiogenesis, still face the problems of insufficient efficacy, resistance and intrinsic refractoriness, in addition to their toxic side effects. There is a demand to identify additional targets that can be blocked to turn off the downstream effects of most, if not all, pathways. Our studies suggest that orphan nuclear receptor TR3 (human)/Nur77 (mouse) is such a target. Most recently, we reported that TR3/Nur77 expression in human hepatic cancer tissues correlates well with tumor progress, suggesting that TR3 is a specific therapeutic target for hepatic cancers. However, the correlation of TR3/Nur77 expression in hepatocellular carcinoma (HCC) with chronic hepatitis has not been studied.Methods: The expression of TR3/Nur77 was analyzed in human primary hepatic cancer specimens from patients that have complete medical records with Immunohistochemically staining. The statistical analysis was used to access the significance of TR3 expression in tumor tissues, cirrhosis tissues and chronic hepatitis tissues with and without hepatitis B virus infection (HBV(+) and HBV(-)), which were obtained from para-tumor tissues.Results: The positive rates of TR3/Nur77 expression in hepatocellular carcinoma, cancerous liver cirrhosis and chronic hepatitis are 66.67%, 30%, and 20%, respectively, which are statistic significant (p<0.05). The positive rates of TR3/Nur77 expression in hepatocellular carcinoma are statistic significant (p<0.05) with 81.25% and 20% in HBV (+) or HBV (-), respectively.Conclusion: The positive expression rate of TR3/Nur77 in hepatocellular carcinoma is higher than that in chronic hepatitis and cirrhosis. The positive rate of TR3/Nur77 expression in hepatocellular carcinoma is higher with HBV infection than that without infection. Our results suggest that TR3/Nur77 plays an important role in the progression of chronic hepatitis, and the occurrence and development of HCC.","PeriodicalId":73658,"journal":{"name":"Journal of clinical & experimental oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5573240/pdf/nihms895577.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9938530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

The Pharmacological Modulation of Ca2+/Camp Intracellular Signaling Pathways and Traditional Antitumoral Pharmaceuticals: A Plausible Multi-target Combined Therapy? 细胞内Ca2+/Camp信号通路的药理调节和传统抗肿瘤药物:一个合理的多靶点联合治疗?

Journal of clinical & experimental oncology

Pub Date : 2017-07-24 DOI: 10.4172/2324-9110.1000e111

P. Errante, S. Francisco, ro Menezes-Rodrigues, A. Caricati‐Neto, Le, ro Bueno Bergantin

Cancer is a major public health issue worldwide, affecting both developed and developing countries, thus leading to the rise of a large annual expenses every fiscal year. Surgery, radiotherapy, chemotherapy, immunotherapy and multitarget pharmaceutical therapies are the current strategies for cancer treatment. Generally, cancer treatments are based on the clinical history of the patients, including histological type and the presence of molecular biomarkers. Nonetheless, new options are clearly needed to increase survival and improve the patients’ quality of life, especially for those in advanced stages of this disease. Thus, the increased knowledge of the mechanisms responsible for growth, invasion and metastasis of cancer, including development of intrinsic resistance, is critical.

癌症是世界范围内的一个主要公共卫生问题，影响到发达国家和发展中国家，因此导致每个财政年度的年度费用增加。手术、放疗、化疗、免疫治疗和多靶点药物治疗是目前癌症治疗的策略。一般来说，癌症的治疗是基于患者的临床病史，包括组织学类型和分子生物标志物的存在。尽管如此，显然需要新的选择来增加生存率和改善患者的生活质量，特别是对于那些处于这种疾病晚期的患者。因此，增加对癌症生长、侵袭和转移机制的了解，包括内在耐药性的发展，是至关重要的。

引用次数: 3

Rho-Kinases in Oral Squamous Cell Carcinoma: A Review 口腔鳞状细胞癌中rho激酶的研究进展

Journal of clinical & experimental oncology

Pub Date : 2017-07-22 DOI: 10.4172/2324-9110.1000189

Anjali P Ganjre, S. Sangamithra, Asmita Kharche

OSCC is most common and lethal malignancy worldwide. Global estimated death is to be more than 10,000 annually. Metastasis is the deadly consequence associated with OSCC because of homing of cancer cells to lymph nodes. Motility of cells is accomplished by important signaling molecule known as Rho kinases. Rhokinases modulates cytoskeleton of “transformed” malignant cell to govern distant metastasis. Interaction of Rho kinases and signaling molecules assists in driving the tumor cell through extracellular matrix and blood vessels to reach the destined location. By focusing and systemizing on the molecular aspect of Rhokinases will help in divulging the problem of the mobility of OSCC cells and will also aid in designing novel anticancer therapies.

OSCC是世界范围内最常见、最致命的恶性肿瘤。据估计，全球每年死亡人数将超过1万人。转移是与OSCC相关的致命后果，因为癌细胞归巢到淋巴结。细胞的运动是由被称为Rho激酶的重要信号分子完成的。罗激酶调节“转化”恶性细胞的细胞骨架，控制远处转移。Rho激酶和信号分子的相互作用有助于驱动肿瘤细胞通过细胞外基质和血管到达预定位置。通过对Rhokinases分子方面的关注和系统化，将有助于揭示OSCC细胞的移动性问题，也将有助于设计新的抗癌疗法。

引用次数: 0

Roles of NAD (P) H-Quinone Oxidoreductase 1 (NQO1) On Cancer Progression and Chemoresistance NAD (P) h -醌氧化还原酶1 (NQO1)在癌症进展和化疗耐药性中的作用

Journal of clinical & experimental oncology

Pub Date : 2017-07-22 DOI: 10.4172/2324-9110.1000192

Pimradasiri Srijiwangsa, K. Na-Bangchang

NAD(P)H-Quinone Oxidoreductase 1 (NQO1), originally referred to as DT-diaphorase, is a xenobiotic metabolizing/antioxidant enzyme that detoxifies chemical stressors, providing cytoprotection in normal tissues. NQO1 catalyzes obligatory two-electron reduction of several endogenous and environmental quinones to hydroquinone that are ready for further conjugation and excretion. The enzyme requires NADH or NADPH as an electron donor for enzymatic activity. High-level of NQO1 expression has however, been correlated with numerous human malignancies, suggesting its role in cancer progression and chemoresistance. This adaptation renders the cancer cells to survive in relatively high oxidative stress condition compared to normal cells, as well as protects cancer cells from toxic action of chemotherapeutic agents. Inhibitors of NQO1 enzyme have been found to improve anticancer activities of conventional chemotherapeutic agents. The review provides a perspective on a molecular basis of NQO1-mediated cancer cells progression and the suppression and possible strategy to improve chemosensitivity and to overcome chemoresistance of NQO1 inhibitors when used in combination with chemotherapeutic drugs.

NAD（P）H-醌氧化还原酶1（NQO1），最初被称为DT黄递酶，是一种异生代谢/抗氧化酶，可对化学应激源进行解毒，为正常组织提供细胞保护。NQO1催化几种内源性和环境醌的强制性双电子还原为氢醌，这些氢醌可以进一步结合和排泄。该酶需要NADH或NADPH作为酶活性的电子供体。然而，高水平的NQO1表达与许多人类恶性肿瘤相关，表明其在癌症进展和化疗耐药性中的作用。与正常细胞相比，这种适应使癌症细胞能够在相对较高的氧化应激条件下存活，并保护癌症细胞免受化疗剂的毒性作用。NQO1酶抑制剂已被发现可提高常规化疗药物的抗癌活性。该综述提供了NQO1介导的癌症细胞进展的分子基础，以及与化疗药物联合使用时提高NQO1抑制剂的化学敏感性和克服其化学耐药性的抑制和可能的策略。

{"title":"Roles of NAD (P) H-Quinone Oxidoreductase 1 (NQO1) On Cancer Progression and Chemoresistance","authors":"Pimradasiri Srijiwangsa, K. Na-Bangchang","doi":"10.4172/2324-9110.1000192","DOIUrl":"https://doi.org/10.4172/2324-9110.1000192","url":null,"abstract":"NAD(P)H-Quinone Oxidoreductase 1 (NQO1), originally referred to as DT-diaphorase, is a xenobiotic metabolizing/antioxidant enzyme that detoxifies chemical stressors, providing cytoprotection in normal tissues. NQO1 catalyzes obligatory two-electron reduction of several endogenous and environmental quinones to hydroquinone that are ready for further conjugation and excretion. The enzyme requires NADH or NADPH as an electron donor for enzymatic activity. High-level of NQO1 expression has however, been correlated with numerous human malignancies, suggesting its role in cancer progression and chemoresistance. This adaptation renders the cancer cells to survive in relatively high oxidative stress condition compared to normal cells, as well as protects cancer cells from toxic action of chemotherapeutic agents. Inhibitors of NQO1 enzyme have been found to improve anticancer activities of conventional chemotherapeutic agents. The review provides a perspective on a molecular basis of NQO1-mediated cancer cells progression and the suppression and possible strategy to improve chemosensitivity and to overcome chemoresistance of NQO1 inhibitors when used in combination with chemotherapeutic drugs.","PeriodicalId":73658,"journal":{"name":"Journal of clinical & experimental oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42160772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 11

Pre-Irradiated Fibroblasts Influence the Chemosensitivity of Co-Cultivated Squamous Cell Carcinoma Cells 预辐照成纤维细胞对共培养鳞状细胞癌细胞化疗敏感性的影响

Journal of clinical & experimental oncology

Pub Date : 2017-06-27 DOI: 10.4172/2324-9110.1000178

Gehrke T, Scherzad A, Hackenberg S, Ickrath P, Schendzielorz P, Hagen R, Kleinsasser N

Objective: Tumor stroma mainly consists of fibroblasts, which have a multitude of interactions with the cancer cells they surround. Since irradiation and chemotherapy are common therapeutic options for squamous cell carcinoma of the head and neck, the effects of irradiation on tumor stroma and their sensitivity to chemotherapeutic agents are of significant therapeutic interest. Methods: FaDu head and neck squamous cell carcinoma cells (HNSCC) were cultivated with fibroblasts from pre-irradiated and non-irradiated human skin for 24 hours. Then the co-cultures were treated with either Cisplatin, Paclitaxel or 5-Fluorouracil for 48 hours. Analysis of tumor viability and apoptosis were conducted via the MTT assay and the Annexin V-propidium iodide test. Secretion of interleukin-8 (IL-8) was analyzed with an enzyme-linked immunosorbent assay. Results: Co-cultures with pre-irradiated fibroblasts showed decreased viability, higher rates of apoptosis and necrosis, and lower levels of IL-8 as compared to co-cultures with non-irradiated fibroblasts in the presence of chemotherapeutic agents as well as in the control group. Conclusion: We therefore postulate an influence of a previous irradiation of fibroblasts on the chemosensitivity of co-cultured tumor cells. To achieve a better understanding of the effects of cytostatic treatment in pre-irradiated head and neck cancer patients, further investigations are warranted.

目的：肿瘤间质主要由成纤维细胞组成，成纤维细胞与周围的癌症细胞有多种相互作用。由于放疗和化疗是头颈部鳞状细胞癌的常见治疗选择，因此放疗对肿瘤间质的影响及其对化疗药物的敏感性具有重要的治疗意义。方法：用预辐照和未辐照的人皮肤成纤维细胞培养法都头颈部鳞状细胞癌细胞（HNSCC）24小时。然后用顺铂、紫杉醇或5-氟尿嘧啶处理共培养物48小时。通过MTT法和膜联蛋白V碘化丙啶试验分析肿瘤的生存能力和细胞凋亡。用酶联免疫吸附法分析白细胞介素-8（IL-8）的分泌。结果：与在化疗药物存在下和对照组中与未照射的成纤维细胞共培养相比，与预照射成纤维细胞的共培养显示出生存能力降低、细胞凋亡和坏死率升高以及IL-8水平降低。结论：因此，我们假设先前对成纤维细胞的照射对共培养的肿瘤细胞的化学敏感性有影响。为了更好地了解放疗前头颈部癌症患者的细胞抑制治疗效果，有必要进行进一步的研究。

{"title":"Pre-Irradiated Fibroblasts Influence the Chemosensitivity of Co-Cultivated Squamous Cell Carcinoma Cells","authors":"Gehrke T, Scherzad A, Hackenberg S, Ickrath P, Schendzielorz P, Hagen R, Kleinsasser N","doi":"10.4172/2324-9110.1000178","DOIUrl":"https://doi.org/10.4172/2324-9110.1000178","url":null,"abstract":"Objective: Tumor stroma mainly consists of fibroblasts, which have a multitude of interactions with the cancer cells they surround. Since irradiation and chemotherapy are common therapeutic options for squamous cell carcinoma of the head and neck, the effects of irradiation on tumor stroma and their sensitivity to chemotherapeutic agents are of significant therapeutic interest. \u0000Methods: FaDu head and neck squamous cell carcinoma cells (HNSCC) were cultivated with fibroblasts from pre-irradiated and non-irradiated human skin for 24 hours. Then the co-cultures were treated with either Cisplatin, Paclitaxel or 5-Fluorouracil for 48 hours. Analysis of tumor viability and apoptosis were conducted via the MTT assay and the Annexin V-propidium iodide test. Secretion of interleukin-8 (IL-8) was analyzed with an enzyme-linked immunosorbent assay. \u0000Results: Co-cultures with pre-irradiated fibroblasts showed decreased viability, higher rates of apoptosis and necrosis, and lower levels of IL-8 as compared to co-cultures with non-irradiated fibroblasts in the presence of chemotherapeutic agents as well as in the control group. \u0000Conclusion: We therefore postulate an influence of a previous irradiation of fibroblasts on the chemosensitivity of co-cultured tumor cells. To achieve a better understanding of the effects of cytostatic treatment in pre-irradiated head and neck cancer patients, further investigations are warranted.","PeriodicalId":73658,"journal":{"name":"Journal of clinical & experimental oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43810018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Expression of Circulating Mir-206 in Patients with Lung and Head and Neck Cancers and its Association with Cancer Cachexia 循环Mir-206在肺癌和头颈癌中的表达及其与癌症恶病质的关系

Journal of clinical & experimental oncology

Pub Date : 2017-06-15 DOI: 10.4172/2324-9110.1000191

N. Sut, Yo, R. Hariani, P. Wuyung, A. Rahmadi, A. Mulawarman, C. Herawati, R. Ramli

Background: cancer cachexia is a common problem found in advanced stage cases. Pathophysiology of cachexia is complicated, involving cytokines and regulator molecules such as microRNA (miRNA). MiR-206, a specific miRNA in skeletal muscle cells was thought to play important role in regulating skeletal muscle loss but have not been studied well in cachectic patients. Objective: to evaluate the clinical significance of circulating miR-206 in cancer patients presenting with cancer cachexia. Method: A cross-sectional study was performed in Dharmais Cancer Hospital, Jakarta between September and December 2015. Patients enrolled were lung and head and neck cancers. Cachexia was defined as body mass index less than 20 kg/m2. MiR-206 expression was assayed using quantitative real-time polymerase chain reaction (RT-PCR), whereas miR-16 served as internal control. The results were expressed as cycle threshold (CT) and fold change (FC) which was calculated using the 2-ΔΔCT method. Results: Seventy patients were enrolled during the study period; consisting 37 (52.9%) lung 33 (47.1%) head and neck cancers. There were 31 (41.3%) patients presenting with cachexia. Serum miR-206 was overexpressed in cancer patients compare to normal healthy subjects. MicroRNA-206 expression was slightly up-regulated in cachectic patients than non-cachectic patients, i.e. FC=1.355 in lung cancers and FC=1.438 in head and neck cancers. Conclusion: Circulating miR-206 is overexpressed advanced stage lung cancer as well as head and neck cancer patients. Increased circulating miR-206 in cachectic patients may reflect extensive skeletal muscle loss associated with cancer cachexia.

背景：癌症恶病质是晚期病例中常见的问题。恶病质的病理生理学是复杂的，涉及细胞因子和调节分子，如微小RNA（miRNA）。MiR-206，一种骨骼肌细胞中的特异性miRNA，被认为在调节骨骼肌损失中发挥重要作用，但尚未在恶病质患者中得到很好的研究。目的：评价循环miR-206在癌症患者癌症恶病质中的临床意义。方法：2015年9月至12月在雅加达癌症Dharmais医院进行横断面研究。入选的患者为肺癌、头颈癌。恶病质定义为体重指数小于20kg/m2。使用定量实时聚合酶链式反应（RT-PCR）测定MiR-206的表达，而MiR-16作为内部对照。结果表示为循环阈值（CT）和倍数变化（FC），使用2-ΔΔCT方法计算。结果：研究期间有70名患者入选；包括37例（52.9%）肺癌33例（47.1%）头颈癌。有31例（41.3%）患者出现恶病质。与正常健康受试者相比，癌症患者血清miR-206过度表达。微RNA-206在恶病质患者中的表达比非恶病质的患者略微上调，即肺癌中的FC=1.355，头颈癌中的FC=1.438。结论：循环miR-206在晚期肺癌癌症和头颈部癌症患者中过表达。恶病质患者中循环miR-206的增加可能反映了与癌症恶病质相关的广泛骨骼肌损失。

{"title":"Expression of Circulating Mir-206 in Patients with Lung and Head and Neck Cancers and its Association with Cancer Cachexia","authors":"N. Sut, Yo, R. Hariani, P. Wuyung, A. Rahmadi, A. Mulawarman, C. Herawati, R. Ramli","doi":"10.4172/2324-9110.1000191","DOIUrl":"https://doi.org/10.4172/2324-9110.1000191","url":null,"abstract":"Background: cancer cachexia is a common problem found in advanced stage cases. Pathophysiology of cachexia is complicated, involving cytokines and regulator molecules such as microRNA (miRNA). MiR-206, a specific miRNA in skeletal muscle cells was thought to play important role in regulating skeletal muscle loss but have not been studied well in cachectic patients. \u0000Objective: to evaluate the clinical significance of circulating miR-206 in cancer patients presenting with cancer cachexia. \u0000Method: A cross-sectional study was performed in Dharmais Cancer Hospital, Jakarta between September and December 2015. Patients enrolled were lung and head and neck cancers. Cachexia was defined as body mass index less than 20 kg/m2. MiR-206 expression was assayed using quantitative real-time polymerase chain reaction (RT-PCR), whereas miR-16 served as internal control. The results were expressed as cycle threshold (CT) and fold change (FC) which was calculated using the 2-ΔΔCT method. \u0000Results: Seventy patients were enrolled during the study period; consisting 37 (52.9%) lung 33 (47.1%) head and neck cancers. There were 31 (41.3%) patients presenting with cachexia. Serum miR-206 was overexpressed in cancer patients compare to normal healthy subjects. MicroRNA-206 expression was slightly up-regulated in cachectic patients than non-cachectic patients, i.e. FC=1.355 in lung cancers and FC=1.438 in head and neck cancers. \u0000Conclusion: Circulating miR-206 is overexpressed advanced stage lung cancer as well as head and neck cancer patients. Increased circulating miR-206 in cachectic patients may reflect extensive skeletal muscle loss associated with cancer cachexia.","PeriodicalId":73658,"journal":{"name":"Journal of clinical & experimental oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48966242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Comparing Gefitinib and Erlotinib With Regard To Brain Metastases Recurrence in EGFR-Mutant Non-Small Cell Lung Cancer Patients 吉非替尼和厄洛替尼对EGFR突变非小细胞肺癌癌症患者脑转移复发的比较

Journal of clinical & experimental oncology

Pub Date : 2017-06-14 DOI: 10.4172/2324-9110.1000190

K. Nakahama, A. Tamiya, Y. Taniguchi, Yoko Naoki, M. Kanazu, S. Atagi

Brain metastases of lung cancer are associated with a poor prognosis. Little research has been conducted to directly compare erlotinib with gefitinib regarding the frequency of central nerve system recurrence. This is the first study to directly compare erlotinib with gefitinib in terms of brain metastases recurrence rates in patients with EGFR-mutant NSCLC who had no brain metastasis at the time of starting TKI treatment. This was a single-center retrospective study. Advanced or recurrent non-small cell lung cancer patients with no brain metastases at the time of starting initial tyrosine kinase inhibitor treatment who received either gefitinib or erlotinib monotherapy were selected. The primary endpoint was the incidence of brain metastases, and secondary endpoints included the objective response rate, progression-free survival, overall survival, and Post-Progression Survival in subgroups based on tyrosine kinase inhibitor treatment and the occurrence of brain metastases. There were 119 patients in the gefitinib group and 13 patients in the erlotinib group. Brain metastases at disease progression were observed in 16 patients in the gefitinib group, and in no patients in the erlotinib group (13.5% vs. 0%, p=0.37). The median overall survival was 29.2 months in the gefitinib group and was not reached in the erlotinib group (p=0.14). The median PPS was 15.5 months in the gefitinib group and 23.7 months in the erlotinib group (p=0.11). Based on the occurrence of brain metastases, Post-Progression Survival was significantly longer in the no brain metastases group (8.0 months vs. 17.9 months, p=0.01). These data showed the possibility of a lower central-nerve-system recurrence rate with erlotinib compared with gefitinib. Post-Progression Survival in patients with brain metastases was significantly shorter than that of patients without brain metastases.

癌症脑转移与预后不良有关。很少有研究直接比较埃洛替尼和吉非替尼的中枢神经系统复发频率。这是第一项直接比较埃洛替尼和吉非替尼在EGFR突变NSCLC患者脑转移复发率的研究，这些患者在开始TKI治疗时没有脑转移。这是一项单中心回顾性研究。选择接受吉非替尼或埃洛替尼单药治疗的癌症晚期或复发患者，在开始初始酪氨酸激酶抑制剂治疗时无脑转移。主要终点是脑转移的发生率，次要终点包括基于酪氨酸激酶抑制剂治疗和脑转移发生率的亚组的客观有效率、无进展生存率、总生存率和进展后生存率。吉非替尼组119例，埃洛替尼组13例。在吉非替尼组的16名患者中观察到疾病进展时的脑转移，埃洛替尼组无患者（13.5%对0%，p=0.37）。吉非替尼组的中位总生存期为29.2个月，埃洛替尼组未达到（p=0.14）。吉非替尼和埃罗替尼组PPS的中位分别为15.5个月和23.7个月（p=0.11）。根据脑转移的发生情况，无脑转移组的进展后生存期明显更长（8.0个月vs.17.9个月，p=0.01）。这些数据表明，与吉非替尼相比，埃洛替尼可能降低中枢神经系统复发率。脑转移患者的进展后生存期明显短于无脑转移患者。

{"title":"Comparing Gefitinib and Erlotinib With Regard To Brain Metastases Recurrence in EGFR-Mutant Non-Small Cell Lung Cancer Patients","authors":"K. Nakahama, A. Tamiya, Y. Taniguchi, Yoko Naoki, M. Kanazu, S. Atagi","doi":"10.4172/2324-9110.1000190","DOIUrl":"https://doi.org/10.4172/2324-9110.1000190","url":null,"abstract":"Brain metastases of lung cancer are associated with a poor prognosis. Little research has been conducted to directly compare erlotinib with gefitinib regarding the frequency of central nerve system recurrence. This is the first study to directly compare erlotinib with gefitinib in terms of brain metastases recurrence rates in patients with EGFR-mutant NSCLC who had no brain metastasis at the time of starting TKI treatment. This was a single-center retrospective study. Advanced or recurrent non-small cell lung cancer patients with no brain metastases at the time of starting initial tyrosine kinase inhibitor treatment who received either gefitinib or erlotinib monotherapy were selected. The primary endpoint was the incidence of brain metastases, and secondary endpoints included the objective response rate, progression-free survival, overall survival, and Post-Progression Survival in subgroups based on tyrosine kinase inhibitor treatment and the occurrence of brain metastases. There were 119 patients in the gefitinib group and 13 patients in the erlotinib group. Brain metastases at disease progression were observed in 16 patients in the gefitinib group, and in no patients in the erlotinib group (13.5% vs. 0%, p=0.37). The median overall survival was 29.2 months in the gefitinib group and was not reached in the erlotinib group (p=0.14). The median PPS was 15.5 months in the gefitinib group and 23.7 months in the erlotinib group (p=0.11). Based on the occurrence of brain metastases, Post-Progression Survival was significantly longer in the no brain metastases group (8.0 months vs. 17.9 months, p=0.01). These data showed the possibility of a lower central-nerve-system recurrence rate with erlotinib compared with gefitinib. Post-Progression Survival in patients with brain metastases was significantly shorter than that of patients without brain metastases.","PeriodicalId":73658,"journal":{"name":"Journal of clinical & experimental oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48364245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0